Cancers harboring mutations in the Kirsten rat sarcoma homolog (KRAS) gene have been
associated with poor prognosis and lack of targeted therapies. KRAS mutations occur in …

Mutations in codon 12 of KRAS have been identified in 13% of non-small cell lung cancer
patients. Developing targeted therapies against KRASG12C mutation has proven to be …

Kirsten Rat Sarcoma viral oncogene homolog (KRAS) is the most frequently altered
oncogene in Non-Small Cell Lung Cancer (NSCLC). KRAS mutant tumors constitute a …

Opinion statement KRASp. G12C mutation occurs in 12% of newly diagnosed advanced
NSCLC and has recently emerged as a positive predictive biomarker for the selection of …

KRAS mutations are one of the most frequent activating alterations in carcinoma. Recent
efforts have witnessed a revolutionary strategy for KRAS G12C inhibitors with exhibiting …

Mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) are among the most
common aberrations in cancer, including non-small cell lung cancer (NSCLC). The lack of …

Simple Summary v-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS) is the most common
driver in NSCLC, and targeting oncogenic KRAS is a major challenge in the treatment of non …

Activating mutations in RAS family proteins are found in~ 25% of all human cancers.
Different solid tumors are correlated with mutations in certain isoforms of RAS, with Kirsten …

Simple Summary KRAS plays an important role in transmitting signals from growth factors on
the outside of the cell to the cell nucleus. It regulates cell proliferation, growth, and survival …

Highlights•In this review, we mainly highlight the drug design, development process, and
history of KRAS G12C inhibitors.•Targeting KRAS mutant with covalent G12C specific …